The overall goal of this proposal is to develop a Community Clinical Oncology Program (CCOP) which will have the specific aims to a) enhance accrual to National Cancer Institute (NCI) approved clinical research treatment and prevention trials b) enhance scientific participation of physicians and nurse coordinators in these protocols c) improve participation of patients who are members of minority groups in these protocols and d) improve the quality of data developed by our cancer program. We are aleady associated with our Research Bases: the Southwest Oncology Group (SW()G), the National Surgical Breast and Bowel Project (NSABP), the Gynecologic Oncology Group (GOG), and the Radiation Therapy Oncology Group (RT()G). The components of the Scott&White CCOP will be the Scott&White Clinic and Memorial Hospital and the Olin E. Tcague Veterans Center (OT- VA) which are 1.5 miles apart in Temple, TX. Our institutions serve a catchment area of one million people of diverse origins and lies in the Central Texas counties between Waco and Austin. The Scott&White Clinic is a for profit multi-disciplinary practice group of 460 physicians, including 9 medical oncoiogists and 4 radiation therapists. There were over one million visits to the Scott&White Clinic in 1995 and the Hospital has 365 acute care beds. The OT-VA is staffed by 92 physicians including 3 medical oncologists and has 135 acute care -s. The Scott & White and OT- VA cancer programs have a record of collaborative association in a) participation in SWGG research protocols b) participation in weekly Division of Hematology and Oncology conferences, residency and medical oncology fellowship programs c) providing clinical experience for Texas A&M medical students. The Scott&White and OT-VA tumor registries recorded 1612 and 506 new, non-skln cancer cases in 1995. We have entered over 50 patients/year onto NCI sponsored tretment trials the last 5 years and 338 patients thus far on the Breast Cancer and Prostate Cancer Prevention Trials. We have an excellent record in regard to quality of data accrual in our clinical trials. We plan to enhance patient accrual in general and specifically, minority patients utilizing multiple strategies to achieve a total of 270 accrual credits/year. These strategies include extensive use of nurse coordinator expertise in screening and recuiting patients, locating research personnel at both the OT-VA and Scott&White, newsletters to participating physicians, monthly research conferences, minority focus groups and outreach clinics to underserved communities of our catchment area. We will utilize data management techniques such as computer data management, enhancing multiple points of communication between coworkers ie research assistants, nurse coordinators and physicians and multiple checks on data quality.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10CA074647-03
Application #
2896006
Study Section
Special Emphasis Panel (ZCA1-RLB-7 (J2))
Project Start
1997-08-01
Project End
2000-05-31
Budget Start
1999-06-01
Budget End
2000-05-31
Support Year
3
Fiscal Year
1999
Total Cost
Indirect Cost
Name
Scott and White Memorial Hospital
Department
Type
DUNS #
076697960
City
Temple
State
TX
Country
United States
Zip Code
76504
Hussain, Maha; Tangen, Catherine M; Thompson Jr, Ian M et al. (2018) Phase III Intergroup Trial of Adjuvant Androgen Deprivation With or Without Mitoxantrone Plus Prednisone in Patients With High-Risk Prostate Cancer After Radical Prostatectomy: SWOG S9921. J Clin Oncol 36:1498-1504
Moinpour, Carol M; Unger, Joseph M; Ganz, Patricia A et al. (2017) Seven-year follow-up for energy/vitality outcomes in early stage Hodgkin's disease patients treated with subtotal lymphoid irradiation versus chemotherapy plus radiation: SWOG S9133 and its QOL companion study, S9208. J Cancer Surviv 11:32-40
Goldkorn, Amir; Ely, Benjamin; Tangen, Catherine M et al. (2015) Circulating tumor cell telomerase activity as a prognostic marker for overall survival in SWOG 0421: a phase III metastatic castration resistant prostate cancer trial. Int J Cancer 136:1856-62
Blumenthal, Deborah T; Rankin, Cathryn; Stelzer, Keith J et al. (2015) A Phase III study of radiation therapy (RT) and O?-benzylguanine + BCNU versus RT and BCNU alone and methylation status in newly diagnosed glioblastoma and gliosarcoma: Southwest Oncology Group (SWOG) study S0001. Int J Clin Oncol 20:650-8
Budd, George T; Barlow, William E; Moore, Halle C F et al. (2015) SWOG S0221: a phase III trial comparing chemotherapy schedules in high-risk early-stage breast cancer. J Clin Oncol 33:58-64
Erba, Harry P; Othus, Megan; Walter, Roland B et al. (2014) Four different regimens of farnesyltransferase inhibitor tipifarnib in older, untreated acute myeloid leukemia patients: North American Intergroup Phase II study SWOG S0432. Leuk Res 38:329-33
Bepler, Gerold; Zinner, Ralph G; Moon, James et al. (2014) A phase 2 cooperative group adjuvant trial using a biomarker-based decision algorithm in patients with stage I non-small cell lung cancer (SWOG-0720, NCT00792701). Cancer 120:2343-51
Smerage, Jeffrey B; Barlow, William E; Hortobagyi, Gabriel N et al. (2014) Circulating tumor cells and response to chemotherapy in metastatic breast cancer: SWOG S0500. J Clin Oncol 32:3483-9
Allen, Jeffrey W; Moon, James; Redman, Mary et al. (2014) Southwest Oncology Group S0802: a randomized, phase II trial of weekly topotecan with and without ziv-aflibercept in patients with platinum-treated small-cell lung cancer. J Clin Oncol 32:2463-70
Philip, Philip A; Goldman, Bryan; Ramanathan, Ramesh K et al. (2014) Dual blockade of epidermal growth factor receptor and insulin-like growth factor receptor-1 signaling in metastatic pancreatic cancer: phase Ib and randomized phase II trial of gemcitabine, erlotinib, and cixutumumab versus gemcitabine plus erlotinib (SWO Cancer 120:2980-5

Showing the most recent 10 out of 97 publications